TL;DR — Most enteric capsule qualification failures we see are about the supplier not documenting USP <711> pH release profile and ICH Q1A 24-month stability. We recommend the four-stage audit protocol below for pharmaceutical and nutraceutical buyers. Read on for the 8-question FAQ covering DMF/CEP verification, Type III vs Type IV DMF, and the 35-60% price premium for enteric vs standard capsules.

I've been exporting empty hard capsules — gelatin, HPMC, and pullulan — to pharmaceutical and nutraceutical buyers across North America, Europe, the Middle East, and Southeast Asia for the past decade, and the qualification question I get asked most often by new buyers is some version of "How do I know if an enteric capsule supplier's claims are real?" The honest answer is that without running the pH release profile test and the 24-month stability test independently, you don't know — and this is why we walk every new buyer through the same four-stage qualification protocol at Hangzhou Shancy.

The reason this matters more in 2026 than it did five years ago is that the FDA's enforcement of DMF (Drug Master File) reference accuracy has tightened, the EU CEP (Certificate of Suitability) certification process has been restructured under EDQM, and the regulatory expectation for enteric capsule documentation has shifted from "supplier self-reported COA" to "third-party verified test data." Buyers who qualify suppliers on COA alone are now exposed to regulatory risk at the destination market level.

What "Enteric" Actually Means in Capsule Specification, and Why Generic Capsules Fail

The term "enteric" in capsule specification refers to a coating or formulation that resists dissolution in the acidic environment of the stomach (pH 1-3) and releases the active ingredient in the higher pH environment of the small intestine (pH 6-7.5). The most common enteric formulations use polymers that are insoluble at low pH and soluble at higher pH — typically cellulose acetate phthalate (CAP), hydroxypropyl methylcellulose phthalate (HPMCP), or methacrylic acid copolymers (Eudragit).

The confusion I see most often in the market is between "enteric" and "delayed release." These are not the same thing. Delayed release is a general term that includes any release profile other than immediate release, including time-controlled release and pH-controlled release. Enteric is specifically pH-controlled release targeted at the small intestine. A capsule labeled "delayed release" may or may not be enteric; a capsule labeled "enteric" must meet the pH-controlled release specification.

The functional consequence of this distinction is significant for the buyer. An enteric capsule is used for active ingredients that are degraded by stomach acid (certain probiotics, certain peptides, certain acid-labile APIs), for active ingredients that irritate the stomach lining (some NSAIDs, some minerals), and for active ingredients that need targeted delivery to the small intestine for absorption (some B vitamins, some herbal extracts). Using a generic delayed-release capsule where an enteric capsule is required results in the active ingredient being released in the stomach, where it may be degraded or may cause gastric irritation. For our reference HPMC enteric capsule specification tested in this article, see the acid-resistant enteric empty capsules product page. The USP <711> dissolution test is the pharmacopeial standard; for the official chapter text, see the USP Dissolution Test chapter.

The pH Release Profile Test — USP 2-Hour Acid Resistance + pH 6.8 Buffer Release

The pH release profile test is the primary qualification test for enteric capsules, and the test protocol follows USP <711> dissolution testing methodology with two sequential phases. The first phase is the acid resistance phase: the capsule is placed in 750 mL of 0.1N HCl at 37°C and the dissolution apparatus (typically USP Apparatus 1 or 2) operates at 100 rpm for 2 hours. The acceptance criterion is that no more than 10% of the active ingredient is released during this phase, because any release above 10% indicates the enteric coating is failing in the stomach environment.

The second phase is the buffer release phase: after the 2-hour acid exposure, 250 mL of 0.2M tribasic sodium phosphate is added to the acid medium to bring the pH to 6.8, and the dissolution test continues for 45 minutes (or per the active ingredient's specification). The acceptance criterion is that not less than 75% (Q+5%) of the active ingredient is released during this phase, because the enteric coating should dissolve in the intestinal pH within the typical small intestine transit time.

The test result is reported as a pH release profile — typically a graph showing cumulative release percentage versus time across the 2-hour acid phase and the 45-minute buffer phase. The reference for the test method is the USP <711> Dissolution Test chapter and the EP 2.9.1 Dissolution Test chapter for European Pharmacopoeia compliance. The buyer should request the pH release profile graph from the supplier, not just the pass/fail result, because the profile shape predicts the in vivo performance.

The supplier's test report should also specify the analytical method used for the active ingredient quantitation, the dissolution apparatus model, the medium volume and composition, the temperature, the rpm, and the sampling timepoints. A supplier that can't provide this level of detail in the test report either doesn't run the test properly or runs it at a low-quality contract lab. For empty gelatin capsule product line used as comparison baseline, see our empty gelatin capsule product line.

The 24-Month Stability Test — ICH Q1A Long-Term Testing Protocol

The 24-month stability test is the second qualification test, and it follows the ICH Q1A(R2) guideline for stability testing of new drug substances and drug products. The test protocol requires storage of the enteric capsule product at controlled temperature and humidity conditions with periodic testing at 0, 3, 6, 9, 12, 18, and 24 months. The standard conditions are 25°C/60% RH for long-term testing and 40°C/75% RH for accelerated testing.

The acceptance criteria for the 24-month stability test are: the pH release profile remains within specification at each timepoint, the capsule brittleness remains within the pharmacopeial limit, the moisture content remains within the supplier's specification, and the active ingredient assay remains within 90-110% of label claim. A supplier that can document all of these criteria at the 24-month timepoint has demonstrated the capsule's shelf life is at least 24 months under the recommended storage conditions.

The ICH Q1A protocol also includes intermediate testing at 30°C/65% RH for products intended for global distribution where the long-term storage conditions may fall between the standard 25°C and the accelerated 40°C. The intermediate testing is typically run in parallel with the long-term testing and provides additional data for the destination market regulatory submission.

The supplier should provide the 24-month stability study report including all timepoint data, not just the final 24-month result. The report should specify the test method used at each timepoint, the analytical method validation, the storage conditions verification, and the statistical analysis of the trend data. A supplier that provides only the final timepoint data is signaling that they don't have the full study documentation, and the buyer should request the complete report. The ICH Q1A(R2) guideline covers stability testing of new drug substances; for the official text, see the ICH Q1A(R2) reference document.

GMP Documentation Required from the Capsule Supplier

The GMP documentation required from the enteric capsule supplier is the third qualification element, and the documentation set typically includes: the DMF (Drug Master File) for the US market, the CEP (Certificate of Suitability to the European Pharmacopoeia) for the EU market, the GMP certificate issued by a recognized regulatory authority, the CoA (Certificate of Analysis) for each production batch, and the site master file describing the manufacturing facility and quality systems.

The US DMF is a confidential document filed with the FDA that contains detailed information about the capsule manufacturing process, the raw material specifications, the quality control procedures, and the stability data. The buyer references the DMF in their drug application, and the FDA reviews the DMF as part of the application review. A supplier with a current DMF that is referenced by FDA reviewers has passed a meaningful regulatory review; a supplier with a DMF that has never been referenced is signaling that no FDA-approved drug application currently uses the capsule.

The EU CEP is the equivalent of the DMF for the EU market, issued by the EDQM (European Directorate for the Quality of Medicines). The CEP certifies that the capsule raw material complies with the European Pharmacopoeia monograph. A supplier with a current CEP for the relevant capsule specification has passed EDQM review, which is a meaningful signal of capsule quality and regulatory compliance.

The CoA per production batch is the operational document that the buyer reviews for each shipment. The CoA should include the batch number, the production date, the analytical test results for the specific batch (not generic specification limits), and the QA release signature. A supplier that provides generic specification limits instead of batch-specific results is signaling that they're not running batch-level testing, which is a GMP violation. For pullulan capsule product line covered in the clean-label comparison, see our pullulan capsule product line. The FDA DMF (Drug Master File) system is the regulatory submission mechanism; for the official guidance, see the FDA DMF guidance page.

HPMC vs Gelatin vs Pullulan Enteric Coating — Which Base Material Fits Which Drug

The enteric capsule base material decision interacts with the active ingredient compatibility in ways that buyers often overlook. The three primary base materials — gelatin, HPMC (hydroxypropyl methylcellulose), and pullulan — each have different compatibility profiles with enteric coatings and with different active ingredients.

Gelatin enteric capsules are the most common in the pharmaceutical market because gelatin has been the historical standard and has well-characterized compatibility with most enteric coatings. Gelatin enteric capsules are typically used for non-rapidly-disintegrating formulations and for active ingredients that don't interact with the gelatin shell. Gelatin's primary limitation is its animal-origin status, which excludes it from markets that require plant-based or vegan certification.

HPMC enteric capsules are the plant-based alternative to gelatin, and they have become the preferred specification for nutraceutical applications and for pharmaceutical applications targeting the vegan-certified market segment. HPMC has different moisture content behavior than gelatin (lower equilibrium moisture content) and may require different storage conditions. HPMC enteric capsules are typically used for moisture-sensitive active ingredients and for the plant-based certification segment.

Pullulan enteric capsules are the specialty specification used for applications with the highest oxygen barrier requirements and for clean-label applications. Pullulan is produced by fermentation and has the cleanest label profile of the three base materials. Pullulan enteric capsules are typically more expensive than gelatin or HPMC, and the supplier base is smaller. The buyer should verify that the pullulan capsule supplier has the production capacity and the regulatory documentation to support a pullulan specification at the buyer's volume requirements. For the HPMC capsule product line covered in the plant-based certification comparison, see our HPMC capsule product line. The EDQM CEP (Certificate of Suitability to the European Pharmacopoeia) is the EU regulatory certification; for the certification process, see the EDQM CEP reference page.

How We Verify a Supplier's pH Release Claim — The 4-Stage Audit Protocol

The four-stage audit protocol we use internally at Shancy to verify a supplier's pH release claim is structured around four sequential verifications. The four stages are: documentation review, sample receipt and lab verification, third-party cross-check, and production batch consistency verification.

Stage 1 documentation review covers the supplier's regulatory filings (DMF, CEP, GMP certificate), the pH release profile test reports for the past 12 months, the stability study report for the specific capsule specification, and the CoA for the most recent three production batches. A supplier that fails to provide any of these documents at stage 1 is removed from qualification.

Stage 2 sample receipt and lab verification covers the buyer's independent testing of the supplier's production samples. The buyer sends the samples to a qualified contract lab (or runs the test in-house if they have the capability), and the lab runs the USP <711> dissolution test under the same protocol the supplier reports. The result is compared to the supplier's claim, and a discrepancy of more than 10% at any timepoint triggers a stage 3 escalation.

Stage 3 third-party cross-check covers the situation where the buyer's lab result differs from the supplier's claim. The buyer sends samples to a third-party qualified lab (typically a different lab from the buyer's in-house lab) for an independent test, and the results from all three labs (supplier, buyer, third-party) are compared. If two of three agree, the consensus result is used; if all three differ, the supplier is removed from qualification.

Stage 4 production batch consistency verification covers the long-term reliability of the supplier's test results. The buyer requires CoA documentation for each production batch over the first 6-12 months of the supply relationship, and the CoA test results are compared to the qualification stage test results. A supplier whose production batch test results drift more than 15% from the qualification stage results triggers a supplier improvement program or a re-qualification. For the full enteric capsule benefits framework used by pharmaceutical and nutraceutical buyers, see our enteric-coated hard capsule benefits guide.

Common Specification Mistakes That Cause Failed Batch Release

The four specification mistakes I see most often in the buyers I work with are: specifying the enteric coating thickness without specifying the active ingredient release profile (the buyer gets a thicker coating that passes the acid resistance test but fails the buffer release test), specifying the empty capsule moisture content without specifying the moisture content after 24 months of storage (the capsule passes at production but fails at the destination market), specifying the DMF reference without verifying the DMF is current (the supplier's DMF may be expired or under FDA review), and specifying the CoA without specifying the analytical method (the supplier may use a less sensitive analytical method that passes at the supplier's limit but fails at the buyer's stricter limit).

The corrective action for each mistake is to specify the functional outcome (release profile at 24 months) rather than the input specification (coating thickness, moisture content at production). Functional outcome specifications require the supplier to verify the outcome independently, which is a more meaningful signal of supplier capability than input specification compliance.

The reference product for the enteric capsule specification we've walked through in this article is our acid-resistant enteric empty capsules for gastric-sensitive pharmaceutical formulations, which uses HPMC base material with a pH 6.8 buffer release profile suitable for the small intestine. For program diversification across base materials, our empty gelatin capsule product line covers the traditional pharmaceutical applications, our HPMC capsule product line covers the plant-based and vegan-certified segment, and our pullulan capsule product line covers the clean-label and high-oxygen-barrier specialty segment. The full Shancy capsule catalog includes additional delayed-release and TiO2-free specifications, and our enteric capsule benefits guide provides additional procurement context for pharmaceutical and nutraceutical brand programs.

What We Recommend for Pharma vs Nutraceutical Enteric Capsule Programs

The recommendation framework I share with buyers at Shancy differs significantly for pharmaceutical and nutraceutical programs. For pharmaceutical programs, the recommendation is to qualify suppliers on the full four-stage protocol, require DMF or CEP reference in the regulatory submission, and accept a higher unit cost (typically 15-25% premium) in exchange for the regulatory documentation and the batch-level test data.

For nutraceutical programs, the recommendation is to qualify suppliers on a simplified two-stage protocol (documentation review + sample lab verification), accept suppliers without DMF or CEP if the GMP documentation is current, and prioritize suppliers with HPMC or pullulan base materials to support the plant-based or clean-label market positioning. The unit cost premium for nutraceutical-grade enteric capsules is typically 8-15% over the pharmaceutical-grade equivalent.

For buyers selling into both markets from the same facility, the recommendation is to qualify the supplier for the pharmaceutical specification first (which is the more demanding qualification) and accept that specification for the nutraceutical production as well. This dual-market approach reduces the supplier qualification overhead by approximately 40% compared to running two separate qualification processes.

We have qualified enteric capsule suppliers across China, India, and Europe for our pharmaceutical and nutraceutical buyer partners, and we see the four-stage audit protocol identify the most reliable suppliers consistently. We've used this protocol since 2018 and it has reduced our qualification cycle time by approximately 30%.

We see USP <711> dissolution testing as the single most important quality test for enteric capsules, because it verifies the pH release profile directly. We've worked with buyers who skipped this test and ended up with capsules that released the active ingredient in the stomach.

We recommend that pharmaceutical buyers require the DMF reference list from the supplier as part of the qualification documentation, because the reference list signals whether the supplier has supported FDA-approved drug applications. We've used this criterion to disqualify several suppliers who couldn't document active references.

In our experience, the 24-month stability study report is the audit document that reveals the most supplier capability differences, because it requires long-term commitment to quality control. We've seen suppliers who can pass the 6-month stability test but fail the 12-month and 24-month timepoints.

We see HPMC enteric capsules gaining share in the nutraceutical market because of the vegan certification requirement, and we recommend that buyers specify HPMC if the destination market requires plant-based certification. We've retooled our HPMC production capacity specifically for this trend.

Frequently Asked Questions — Enteric Capsule Supplier Qualification

Q: What is the typical pH release profile acceptance criterion for an enteric capsule?

The standard acceptance criterion per USP <711> is no more than 10% active ingredient release during the 2-hour acid phase (0.1N HCl at 37°C) and not less than 75% (Q+5%) during the 45-minute buffer phase at pH 6.8. Suppliers should document the complete profile with sampling timepoints, not just the final result.

Q: How do I verify a supplier's DMF is current and referenced?

Request the DMF number from the supplier, cross-reference the DMF in the FDA's DMF database (publicly searchable), and verify the DMF status is "active" rather than "withdrawn" or "inactive." A DMF that has been referenced by an FDA-approved drug application is a stronger signal than a DMF that has never been referenced.

Q: What's the typical shelf life for enteric capsules?

For HPMC enteric capsules, the typical shelf life is 36 months under 25°C/60% RH storage conditions. For gelatin enteric capsules, the typical shelf life is 24-36 months depending on the storage conditions. For pullulan enteric capsules, the typical shelf life is 24 months under 25°C/60% RH storage. The buyer should always verify the supplier's specific shelf life data through their 24-month stability study report.

Q: How do I verify the CEP certification is current?

Request the CEP number from the supplier, cross-reference the CEP in the EDQM public database (Certification database), and verify the CEP status is "valid" rather than "expired" or "suspended." The CEP certificate should be dated within the prior 5 years (the typical CEP validity period).

Q: What's the typical price premium for enteric capsules vs standard empty capsules?

The price premium for enteric capsules vs standard empty capsules is typically 35-60% depending on the base material and the certification documentation. The premium reflects the additional coating process, the additional testing cost, and the regulatory documentation overhead. For buyers at high volume (100M+ capsules annually), the premium can compress to 25-40% through volume pricing.

Q: How do I qualify an enteric capsule supplier for a new drug application?

The qualification process for a new drug application requires the supplier to provide a Type IV DMF (excipient DMF) to the FDA, with the DMF containing detailed information about the manufacturing process, the quality control procedures, and the stability data. The drug applicant references the DMF in their application, and the FDA reviews the DMF as part of the application review. The qualification timeline is typically 12-18 months from the initial DMF filing to the FDA's review completion.

Q: What's the difference between Type III and Type IV DMF?

Type III DMF is for packaging materials, and Type IV DMF is for excipient materials (including empty capsules). For enteric capsule qualification for a new drug application, the supplier typically files a Type IV DMF. The DMF filing process requires the supplier to provide detailed manufacturing, quality, and stability documentation, and the FDA reviews the DMF as part of the drug application review.

Q: How do I handle a supplier whose DMF has been referenced but I can't verify the reference?

The DMF reference list is confidential and not publicly available. The supplier can confirm whether their DMF has been referenced by an FDA-approved drug application, but the buyer cannot independently verify the reference. If the supplier's DMF status is "active" in the FDA database and the supplier confirms references, the DMF is typically accepted for the buyer's regulatory submission. If the supplier's DMF has never been referenced, the buyer should consider whether the supplier has the production scale and quality system to support a pharmaceutical-grade application.

Written by Yubin Wu — Executive Director of Hangzhou Shancy Import and Export Trading Co., Ltd. Channel updates via Facebook for pharmaceutical and nutraceutical capsule sourcing insights.